. (1972). Archives of Disease in Childhood, 47, 34. Experience of routine live-birth screening for galactosaemia in a British hospital, with emphasis on heterozygote detection. Results are reported of a screening programme for galactosaemia covering a period of 2A years and 6415 births. The gene frequency for galactosaemia estimated from the data of the screening programme was 0-002. This conflicted with the known livebirth incidence of at least 1: 50,000 during this same period. 2 of the 4 galactosaemic infants concerned died under circumstances that were preventable had they been screened at birth. The need to screen all sick infants for galactosaemia is emphasized, as is the requirement for reliable information on its incidence in Great Britain. The screening test employed (Beutler and Baluda, 1966a) 
Several techniques are now available which permit screening for galactosaemia. Schwarz (1963) described a method based on liberation of CO2 from blood incubated with galactose-lphosphate. A variation of this procedure measures the liberation of C1402 from radioactive galactose (London, Marymont, and Fuld, 1964) . Other methods utilize chromatographic separation of the labelled metabolites produced from radioactive galactose (Robinson, 1963; Tron and Milhaud, 1969) . These tests are valuable diagnostic aids but are too complex for mass screening. An automated blood galactose test has been proposed (Tengstrom, 1969) , but this is only relevant for milk-fed infants and is unlikely to permit heterozygote detection.
The most promising tests for screening purposes are those developed by Beutler. The first utilizes decolorization of methylene blue as the end-point of a reaction sequence starting with galactose-lphosphate (Beutler, Baluda, and Donnell, 1964) as shown in the Fig., and the time taken for decolorization is measured. The second and more convenient test is similar in principle. The reaction sequence is identical with the above (Fig.) but the end-point Received 29 July 1971. comprises the fluorescence due to NADPH which may readily be observed under UV light by spotting an aliquot of the test mixture on paper after 2 hours' incubation (Beutler and Baluda, 1966a) . Both tests have been validated as screening procedures (Gatti, Manfield, and Hsia, 1966; Nelson and Hsia, 1967) . It has been stated that the methylene blue test provides more accurate diagnosis of heterozygotes (Camus, Farriaux, and Fontaine, 1968) , but the fluorescent spot test was preferred by Beutler for mass screening because of its simplicity, especially when applied to blood dried on filter-paper, though he reported difficulties in diagnosing heterozygotes .
Despite the availability of these techniques, screening for galactosaemia has never been proposed as a mandatory test in the newborn. In Reagents. The following mixture was prepared: 2-4 ml UDP-glucose, 9-5 mM; 4 -8 ml galactose-1-phosphate, 27 mM; 0 -36 ml EDTA, disodium salt, 27 mM; 9-6 ml saponin, 1% (w/v); 11 6 ml water. 4 The mixture was accurately dispensed in aliquots of exactly 4 0 ml and stored at -20 'C until required. adjacent to the first spot from that tube. 72 pairs of spots were applied to each sheet of paper 24 cm2. Each sheet contained samples from 2 known galactosaemic and 2 known heterozygote bloods that had been through the complete procedure as a quality control check on the reagents.
Interpretation. After being thoroughly dried, the paper was examined in a darkroom under long wave UV light. Normal blood samples fluoresce brightly at both time intervals. Blood samples from galactosaemic subjects remain dark at both intervals. Samples from galactosaemic heterozygotes and Duarte Variant homozygotes are dim at 1 hour but are indistinguishable from normals at 2 hours. Some samples associated with high Hb content are dim at 1 hour when they resemble the appearance of heterozygote samples but are clearly distinguishable from galactosaemic samples; at 2 hours they continue to present a dim appearance in contrast to heterozygote samples which then fluoresce normally; this distinction can be confirmed by examining the paper in ordinary light when the intense red spot can be easily seen. This phenomenon is due to quenching of the fluorescence by the large amount of haemoglobin present, and since fluorescence is maximal at 1 hour and quenching is independent of time, no change is evident after another hour. The effect of high Hb content in a heterozygote sample is to produce an appearance at both intervals not easily distinguishable from that found with a galactosaemic sample, though once again examination of the paper in natural light will reveal an intense red spot. A similar UV pattern is obtained with samples from profoundly anaemic infants, or when clotting of the specimen has occurred and led to aspiration of material containing few erythrocytes. In these instances, however, it is possible to observe, by examining the paper in natural light, that the spot is much paler than usual.
Follow-up. Whenever screening indicated that an infant was galactosaemic, or a heterozygote, a repeat sample was sought and an attempt was made to obtain venous blood from both parents. These samples were put through the screening test, and assayed quantitatively and in duplicate for erythrocyte galactose-l-phosphate uridyl transferase activity by the method of Beutler and Baluda (1966b) , results being expressed as itmoles UDP-glucose consumed per hour per g Hb (U/g Hb).
In those cases where a discrepancy between the results of screening and quantitative enzyme assay was found, the sample was checked to exclude deficiencies of glucose-6-phosphate and 6-phosphogluconate dehydrogenases; no such deficiencies were encountered in the present clinical material.
Results
Accuracy of screening test. 38 samples drawn from subjects of known genetic status were screened by 5 members of the laboratory staff carrying out the test for the first time. All underestimated the incidence of normal subjects in the material examined (Table I) , and all observers classified one or more of the heterozygotes as galactosaemic. This suggests that the incidence of galactosaemics and of heterozygotes would be overestimated if classification depended on the results of the screening test alone. From the subsequent results it is clear that more than half the infants originally classified as heterozygote turned out to be normal on follow-up. However, out of 45 parents, sibs, and propositi put through routine screening as part of the follow-up procedure and subsequently proven to be heterozygotes by quantitative enzyme assay, 10 escaped detection. Occasional samples contained large clots; when the results of such samples were equivocal, we tended to ascribe the phenomenon to the presence of clots and reported such cases as normal rather than recall the infant and parents for further testing. We feel that a 25% correction is needed to allow for those heterozygotes likely to have been missed through both sources of error. It is perplexing that equal mixtures of normal and galactosaemic blood never resulted in a spot indicative of a heterozygous status.
In routine practice, most normal subjects could be identified by the 1-hour spot. The 2-hour spot mainly served to pinpoint heterozygous and galactosaemic subjects, and those spots showing marked quenching due to a high Hb content. The improved accuracy resulting from examination at both 1 and 2 hours compared with classification of the same cases at a single time, especially where inexperienced observers are concerned, is shown in Table II. Genetic status of population screened. Of the 6415 infants screened during this survey, representing all but 14 of the total live-births during this same period, 5 were reported as galactosaemic. Of these, 2 were ultimately classified as 36 normal and 2 as heterozygotes for galactosaemia (Table III) . The fifth case was discharged home before the result was known and blood could not be obtained for re-examination, but the child was reported to be thriving at 1 year: the original specimen from this child had been mislaid for a period of 3 weeks before testing, so that loss of enzyme activity could explain the misclassification. In all, 36 infants were reported as heterozygous for galactosaemia. Of these, 7 could not be reexamined, but all were well according to information received from their general practitioners. Of the 29 remaining, 18 were classified as normal, 9 as true heterozygotes for classical galactosaemia, and 1 each as homozygous and heterozygous for the gene of the Duarte Variant (Table IV) . This classification, based mainly upon data for quantitative erythrocyte galactose-l-phosphate uridyl transferase activity of the infant and one or both parents is necessarily arbitrary because of overlap between the various genetic groups. In previous work we found that 95 % of normals gave values between 13 and 30 U/g Hb, whereas heterozygotes ranged from 8 to 13 * 4 U/g Hb (Ellis and Goldberg, 1969 the blood urea exceeding 400 mg/100 ml. The second case was referred from another hospital with the diagnosis of Rh-haemolytic disease and septicaemia. He had been well until the 5th day when jaundice and pyrexia developed.
Laboratory results sent with the child indicated a serum bilirubin of 21*9 mg/100 ml and blood sugar 332 mg/100 ml (reducing sugar method). The child was moribund on admission and died within 24 hours on the 10th day. Investigations before death included a Hb estimation of 130% and blood sugar undetectable (glucose oxidase method).
The only sib of this infant died a year before on the 4th day under unexplained circumstances. It is probable that both children would be alive today had routine screening been carried out at birth, or as soon as the infants became ill. The total live-births in the Sheffield Region during the period of this investigation approximated 200,000. The incidence of cases known to us is thus 1: 50,000 and we cannot exclude the possibility of other cases having been diagnosed without referral to our laboratory, or having died = Duarte beterozygote; N Normal. without diagnosis. This estimate is greatly at odds with the figure of 1: 250,000 calculated from the results of our routine screening programme.
Discussion
The fluorescent spot test of Beutler and Baluda (1966a) appears to be a reliable test for galactosaemia homozygotes. We feel confident that no positive case has eluded detection in our series, since all infants were routinely subjected to clinical examination 6 to 8 weeks after birth. Moreover, the tests were performed almost entirely by laboratory technical staff, as many as 6 different technicians being concerned over the period described. A normal result therefore effectively serves (Holzel, Komrower, and Schwarz, 1957; Hsia and Walker, 1961; Hsia, 1967; Woolf, 1968; Hansen, 1969 (Sturgeon, Beutler, and McQuiston, 1967; Hochella and Hill, 1969) and should be capable of heterozygote detection. The capital cost of the required apparatus is about £3000 and the reagent costs 25p per test. Before the case for instituting screening programmes based on these procedures can be entertained, it is essential to know the true incidence of galactosaemia in the British population. Estimates based upon reports in the literature are presented in Table V . These show great variability, partly because they may reflect genuine alterations in gene frequency among different ethnic groups, and partly because, as in the present data, allowance has not been made (except in the report Feigl, 1968) for the Duarte Variant. This genetic abnormality at the galactose-l-phosphate uridyl transferase locus is, in its homozygous (Beutler et al., 1965 , and can be distinguished with certainty from the heterozygous form of classical galactosaemia only by the appearance of abnormal bands on enzyme electrophoresis (Mathai and Beutler, 1966; Ng et al., 1969) . Since galactosaemia can apparently arise as a consequence of mutation (Kelly, Dzierwa, and Baswell, 1968; Meilman et al., 1970) discrepancies are likely to occur between estimates based upon gene frequency and those based upon live-births.
There is a real need to obtain authoritative data on the expected incidence of galactosaemia in this country so that a proper assessment can be made of the likely benefits of live-birth screening in relation to the resources required.
